MEX-NM-301<\/a> <\/p><\/blockquote>\n\n\n\n<\/p>\n","protected":false},"excerpt":{"rendered":"
MEX-NM-301 clinical study opens at I-Motion. This open-label, non-comparative phase III study aims to evaluate the steady-state pharmacokinetics, safety, and efficacy of Mexiletine in adolescents and children with Myotonic disorders. Mexiletine is a sodium channel blocker indicated, in adult, in France, for the symptomatic treatment of myotonic syndromes (myotonic dystrophies and non-dystrophic myotonias or channelopathies). … Continued<\/a><\/p>\n","protected":false},"author":3,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[3],"tags":[],"class_list":["post-2394","post","type-post","status-publish","format-standard","hentry","category-uncategorized"],"acf":[],"yoast_head":"\nOpening of the phase III study evaluating mexiletine in children and adolescents with myotonic disorders - I-Motion<\/title>\n<meta name=\"description\" content=\"L'essai clinique de phase III, MEX-NM-301, d\u00e9marre \u00e0 I-Motion.MEX-NM-301 clinical study opens at I-Motion.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.institut-myologie.org\/imotion\/2021\/08\/23\/ouverture-de-letude-de-phase-iii-evaluant-la-mexiletine-chez-lenfant-et-ladolescent-presentant-des-troubles-myotoniques\/?lang=en\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Opening of the phase III study evaluating mexiletine in children and adolescents with myotonic disorders - I-Motion\" \/>\n<meta property=\"og:description\" content=\"L'essai clinique de phase III, MEX-NM-301, d\u00e9marre \u00e0 I-Motion.MEX-NM-301 clinical study opens at I-Motion.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.institut-myologie.org\/imotion\/2021\/08\/23\/ouverture-de-letude-de-phase-iii-evaluant-la-mexiletine-chez-lenfant-et-ladolescent-presentant-des-troubles-myotoniques\/?lang=en\" \/>\n<meta property=\"og:site_name\" content=\"I-Motion\" \/>\n<meta property=\"article:published_time\" content=\"2021-08-23T12:31:52+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2021-08-23T12:40:52+00:00\" \/>\n<meta name=\"author\" content=\"Anne Berthomier\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"\u00c9crit par\" \/>\n\t<meta name=\"twitter:data1\" content=\"Anne Berthomier\" \/>\n\t<meta name=\"twitter:label2\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/www.institut-myologie.org\/imotion\/2021\/08\/23\/ouverture-de-letude-de-phase-iii-evaluant-la-mexiletine-chez-lenfant-et-ladolescent-presentant-des-troubles-myotoniques\/?lang=en#article\",\"isPartOf\":{\"@id\":\"https:\/\/www.institut-myologie.org\/imotion\/2021\/08\/23\/ouverture-de-letude-de-phase-iii-evaluant-la-mexiletine-chez-lenfant-et-ladolescent-presentant-des-troubles-myotoniques\/?lang=en\"},\"author\":{\"name\":\"Anne Berthomier\",\"@id\":\"https:\/\/www.institut-myologie.org\/imotion\/#\/schema\/person\/ecf0b87715a026a200491fe2d7649def\"},\"headline\":\"Opening of the phase III study evaluating mexiletine in children and adolescents with myotonic disorders\",\"datePublished\":\"2021-08-23T12:31:52+00:00\",\"dateModified\":\"2021-08-23T12:40:52+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/www.institut-myologie.org\/imotion\/2021\/08\/23\/ouverture-de-letude-de-phase-iii-evaluant-la-mexiletine-chez-lenfant-et-ladolescent-presentant-des-troubles-myotoniques\/?lang=en\"},\"wordCount\":74,\"publisher\":{\"@id\":\"https:\/\/www.institut-myologie.org\/imotion\/#organization\"},\"articleSection\":[\"Uncategorized\"],\"inLanguage\":\"fr-FR\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.institut-myologie.org\/imotion\/2021\/08\/23\/ouverture-de-letude-de-phase-iii-evaluant-la-mexiletine-chez-lenfant-et-ladolescent-presentant-des-troubles-myotoniques\/?lang=en\",\"url\":\"https:\/\/www.institut-myologie.org\/imotion\/2021\/08\/23\/ouverture-de-letude-de-phase-iii-evaluant-la-mexiletine-chez-lenfant-et-ladolescent-presentant-des-troubles-myotoniques\/?lang=en\",\"name\":\"Opening of the phase III study evaluating mexiletine in children and adolescents with myotonic disorders - I-Motion\",\"isPartOf\":{\"@id\":\"https:\/\/www.institut-myologie.org\/imotion\/#website\"},\"datePublished\":\"2021-08-23T12:31:52+00:00\",\"dateModified\":\"2021-08-23T12:40:52+00:00\",\"description\":\"L'essai clinique de phase III, MEX-NM-301, d\u00e9marre \u00e0 I-Motion.MEX-NM-301 clinical study opens at I-Motion.\",\"breadcrumb\":{\"@id\":\"https:\/\/www.institut-myologie.org\/imotion\/2021\/08\/23\/ouverture-de-letude-de-phase-iii-evaluant-la-mexiletine-chez-lenfant-et-ladolescent-presentant-des-troubles-myotoniques\/?lang=en#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.institut-myologie.org\/imotion\/2021\/08\/23\/ouverture-de-letude-de-phase-iii-evaluant-la-mexiletine-chez-lenfant-et-ladolescent-presentant-des-troubles-myotoniques\/?lang=en\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.institut-myologie.org\/imotion\/2021\/08\/23\/ouverture-de-letude-de-phase-iii-evaluant-la-mexiletine-chez-lenfant-et-ladolescent-presentant-des-troubles-myotoniques\/?lang=en#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.institut-myologie.org\/imotion\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Opening of the phase III study evaluating mexiletine in children and adolescents with myotonic disorders\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.institut-myologie.org\/imotion\/#website\",\"url\":\"https:\/\/www.institut-myologie.org\/imotion\/\",\"name\":\"I-Motion\",\"description\":\"Plateforme d'essais cliniques p\u00e9diatriques pour les maladies neuromusculaires\",\"publisher\":{\"@id\":\"https:\/\/www.institut-myologie.org\/imotion\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.institut-myologie.org\/imotion\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.institut-myologie.org\/imotion\/#organization\",\"name\":\"Institut I-Motion\",\"url\":\"https:\/\/www.institut-myologie.org\/imotion\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/www.institut-myologie.org\/imotion\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.institut-myologie.org\/imotion\/wp-content\/uploads\/2016\/08\/logoImotion.png\",\"contentUrl\":\"https:\/\/www.institut-myologie.org\/imotion\/wp-content\/uploads\/2016\/08\/logoImotion.png\",\"width\":150,\"height\":51,\"caption\":\"Institut I-Motion\"},\"image\":{\"@id\":\"https:\/\/www.institut-myologie.org\/imotion\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.institut-myologie.org\/imotion\/#\/schema\/person\/ecf0b87715a026a200491fe2d7649def\",\"name\":\"Anne Berthomier\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/www.institut-myologie.org\/imotion\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/86282695a210f7767b59efc8eb542fb81270ad9c1a9d8bb3bccd9ab2f96782e6?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/86282695a210f7767b59efc8eb542fb81270ad9c1a9d8bb3bccd9ab2f96782e6?s=96&d=mm&r=g\",\"caption\":\"Anne Berthomier\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Opening of the phase III study evaluating mexiletine in children and adolescents with myotonic disorders - I-Motion","description":"L'essai clinique de phase III, MEX-NM-301, d\u00e9marre \u00e0 I-Motion.MEX-NM-301 clinical study opens at I-Motion.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.institut-myologie.org\/imotion\/2021\/08\/23\/ouverture-de-letude-de-phase-iii-evaluant-la-mexiletine-chez-lenfant-et-ladolescent-presentant-des-troubles-myotoniques\/?lang=en","og_locale":"fr_FR","og_type":"article","og_title":"Opening of the phase III study evaluating mexiletine in children and adolescents with myotonic disorders - I-Motion","og_description":"L'essai clinique de phase III, MEX-NM-301, d\u00e9marre \u00e0 I-Motion.MEX-NM-301 clinical study opens at I-Motion.","og_url":"https:\/\/www.institut-myologie.org\/imotion\/2021\/08\/23\/ouverture-de-letude-de-phase-iii-evaluant-la-mexiletine-chez-lenfant-et-ladolescent-presentant-des-troubles-myotoniques\/?lang=en","og_site_name":"I-Motion","article_published_time":"2021-08-23T12:31:52+00:00","article_modified_time":"2021-08-23T12:40:52+00:00","author":"Anne Berthomier","twitter_card":"summary_large_image","twitter_misc":{"\u00c9crit par":"Anne Berthomier","Dur\u00e9e de lecture estim\u00e9e":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.institut-myologie.org\/imotion\/2021\/08\/23\/ouverture-de-letude-de-phase-iii-evaluant-la-mexiletine-chez-lenfant-et-ladolescent-presentant-des-troubles-myotoniques\/?lang=en#article","isPartOf":{"@id":"https:\/\/www.institut-myologie.org\/imotion\/2021\/08\/23\/ouverture-de-letude-de-phase-iii-evaluant-la-mexiletine-chez-lenfant-et-ladolescent-presentant-des-troubles-myotoniques\/?lang=en"},"author":{"name":"Anne Berthomier","@id":"https:\/\/www.institut-myologie.org\/imotion\/#\/schema\/person\/ecf0b87715a026a200491fe2d7649def"},"headline":"Opening of the phase III study evaluating mexiletine in children and adolescents with myotonic disorders","datePublished":"2021-08-23T12:31:52+00:00","dateModified":"2021-08-23T12:40:52+00:00","mainEntityOfPage":{"@id":"https:\/\/www.institut-myologie.org\/imotion\/2021\/08\/23\/ouverture-de-letude-de-phase-iii-evaluant-la-mexiletine-chez-lenfant-et-ladolescent-presentant-des-troubles-myotoniques\/?lang=en"},"wordCount":74,"publisher":{"@id":"https:\/\/www.institut-myologie.org\/imotion\/#organization"},"articleSection":["Uncategorized"],"inLanguage":"fr-FR"},{"@type":"WebPage","@id":"https:\/\/www.institut-myologie.org\/imotion\/2021\/08\/23\/ouverture-de-letude-de-phase-iii-evaluant-la-mexiletine-chez-lenfant-et-ladolescent-presentant-des-troubles-myotoniques\/?lang=en","url":"https:\/\/www.institut-myologie.org\/imotion\/2021\/08\/23\/ouverture-de-letude-de-phase-iii-evaluant-la-mexiletine-chez-lenfant-et-ladolescent-presentant-des-troubles-myotoniques\/?lang=en","name":"Opening of the phase III study evaluating mexiletine in children and adolescents with myotonic disorders - I-Motion","isPartOf":{"@id":"https:\/\/www.institut-myologie.org\/imotion\/#website"},"datePublished":"2021-08-23T12:31:52+00:00","dateModified":"2021-08-23T12:40:52+00:00","description":"L'essai clinique de phase III, MEX-NM-301, d\u00e9marre \u00e0 I-Motion.MEX-NM-301 clinical study opens at I-Motion.","breadcrumb":{"@id":"https:\/\/www.institut-myologie.org\/imotion\/2021\/08\/23\/ouverture-de-letude-de-phase-iii-evaluant-la-mexiletine-chez-lenfant-et-ladolescent-presentant-des-troubles-myotoniques\/?lang=en#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.institut-myologie.org\/imotion\/2021\/08\/23\/ouverture-de-letude-de-phase-iii-evaluant-la-mexiletine-chez-lenfant-et-ladolescent-presentant-des-troubles-myotoniques\/?lang=en"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.institut-myologie.org\/imotion\/2021\/08\/23\/ouverture-de-letude-de-phase-iii-evaluant-la-mexiletine-chez-lenfant-et-ladolescent-presentant-des-troubles-myotoniques\/?lang=en#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.institut-myologie.org\/imotion\/"},{"@type":"ListItem","position":2,"name":"Opening of the phase III study evaluating mexiletine in children and adolescents with myotonic disorders"}]},{"@type":"WebSite","@id":"https:\/\/www.institut-myologie.org\/imotion\/#website","url":"https:\/\/www.institut-myologie.org\/imotion\/","name":"I-Motion","description":"Plateforme d'essais cliniques p\u00e9diatriques pour les maladies neuromusculaires","publisher":{"@id":"https:\/\/www.institut-myologie.org\/imotion\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.institut-myologie.org\/imotion\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Organization","@id":"https:\/\/www.institut-myologie.org\/imotion\/#organization","name":"Institut I-Motion","url":"https:\/\/www.institut-myologie.org\/imotion\/","logo":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.institut-myologie.org\/imotion\/#\/schema\/logo\/image\/","url":"https:\/\/www.institut-myologie.org\/imotion\/wp-content\/uploads\/2016\/08\/logoImotion.png","contentUrl":"https:\/\/www.institut-myologie.org\/imotion\/wp-content\/uploads\/2016\/08\/logoImotion.png","width":150,"height":51,"caption":"Institut I-Motion"},"image":{"@id":"https:\/\/www.institut-myologie.org\/imotion\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/www.institut-myologie.org\/imotion\/#\/schema\/person\/ecf0b87715a026a200491fe2d7649def","name":"Anne Berthomier","image":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.institut-myologie.org\/imotion\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/86282695a210f7767b59efc8eb542fb81270ad9c1a9d8bb3bccd9ab2f96782e6?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/86282695a210f7767b59efc8eb542fb81270ad9c1a9d8bb3bccd9ab2f96782e6?s=96&d=mm&r=g","caption":"Anne Berthomier"}}]}},"_links":{"self":[{"href":"https:\/\/www.institut-myologie.org\/imotion\/wp-json\/wp\/v2\/posts\/2394","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.institut-myologie.org\/imotion\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.institut-myologie.org\/imotion\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.institut-myologie.org\/imotion\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/www.institut-myologie.org\/imotion\/wp-json\/wp\/v2\/comments?post=2394"}],"version-history":[{"count":5,"href":"https:\/\/www.institut-myologie.org\/imotion\/wp-json\/wp\/v2\/posts\/2394\/revisions"}],"predecessor-version":[{"id":2403,"href":"https:\/\/www.institut-myologie.org\/imotion\/wp-json\/wp\/v2\/posts\/2394\/revisions\/2403"}],"wp:attachment":[{"href":"https:\/\/www.institut-myologie.org\/imotion\/wp-json\/wp\/v2\/media?parent=2394"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.institut-myologie.org\/imotion\/wp-json\/wp\/v2\/categories?post=2394"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.institut-myologie.org\/imotion\/wp-json\/wp\/v2\/tags?post=2394"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}